Anavex Life Sciences Corp.
↗New York, United States
Anavex Life Sciences is a person-focused, biopharmaceutical company dedicated to therapeutic discovery and development of targeted CNS (central nervous system) treatments. The company develops innovative precision medicine therapeutics addressing neurodegenerative, neurodevelopmental, and neuropsychiatric disorders, with a focus on Alzheimer's disease, Parkinson's disease dementia, schizophrenia, Rett syndrome, and other CNS disorders, as well as pain and cancer. Anavex leverages its proprietary SIGMACEPTOR™ platform technology to develop orally available therapeutic candidates targeting SIGMAR1 (sigma-1 receptor) and muscarinic receptors. The company is recognized as a clinical-stage biopharmaceutical company with multiple mid- to late-stage clinical programs and a strong intellectual property portfolio.
CLASSIFICATION
SIZE & FINANCIALS
Employees:51-200
Revenue:$8M
Founded:2004
Ownership:public
Status:operating
FUNDING
Stage:Public
Investors:Deep Track Capital
STOCK
Exchange:NASDAQ
Ticker:AVXL
Market Cap:$819M
PIPELINE
Stage:Phase 2|Phase 3
Lead Drug Stage:Phase 2b/3 (Blarcamesine/ANAVEX 2-73)
Modalities:Small molecule, Oral therapeutics
Active Trials:4
Trial Phases:Phase 1: 1 | Phase 2: 3 | Phase 3: 2
FDA Approvals:0
EMA Approvals:0
CORPORATE STRUCTURE
Key Partnerships:Partex Group (AI-enabled drug development and patient app ecosystem), Rett Syndrome Foundation (research funding), Michael J Fox Foundation (Parkinson's disease research support)
COMPETITION
Position:Emerging
Competitors:Biogen, Eli Lilly, Eisai, AC Immune, Prothena, Alector, Vaxxinity, Annovis Bio +5 more
LEADERSHIP
Key Executives:
Christopher U. Missling, PhD, MBA - President & CEO
Edward R Hammond - Chief Medical Officer
Walter E Kaufmann - Chief Scientific Officer
Stephan Toutain - Senior Vice President, Operations
Juan Carlos Lopez-Talavera, MD, PhD - Senior Vice President, Head of Research & Development
Terrie Kellmeyer, PhD - Senior Vice President
Board Members:Christopher U. Missling, PhD, MBA (Director), Tasos Zografidis, MS, PhD (Board Member), Bernd Metzner, PhD (Board Member), Elliot Favus, MD (Board Member), Tom Skarpelos (Board Member), Steffen Thomas, PhD (Board Member)
LINKS
⚠
Is this information incorrect? This profile was AI-generated from publicly available sources and may contain errors. If you are a representative of Anavex Life Sciences Corp. and believe any information on this page is inaccurate, we will promptly correct or remove it.REPORT AN ERROR
Disclaimer: IntuitionLabs.ai is not affiliated with, endorsed by, or associated with Anavex Life Sciences Corp.. The information on this page was compiled using AI from publicly available sources and may be incomplete, outdated, or contain errors. We are committed to correcting inaccuracies promptly upon notice. For official information, please visit the company's website directly.